Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

  • Leerink recently hosted 24 biopharmaceutical companies at a roundtable event.
  • Of the 24 companies, Leerink now rates 20 of them as Outperform.
  • Many of these 20 companies have strong potential catalysts coming relatively soon.
  • Leerink Partners recently hosted a Rare Disease Roundtable that included fireside chats with 24 biopharmaceutical companies. Following the event, analyst Joseph Schwartz released a report that included a list of 20 Outperform-rated names that attended the roundtable.

    Here’s a list of some of the potential catalysts Schwartz sees for these companies.

    Highlighted Stocks And Catalysts

  • Aegerion Pharmaceuticals, Inc. AEGR: The company is guiding conservatively for Juxtapid sales.
  • Agios Pharmaceuticals Inc AGIO: The company is seeing clinical benefit in solid tumor indications.
  • Alnylam Pharmaceuticals, Inc. ALNY: The company reports solid enrollment in APOLLO Ph. III trial and positive OLE Phase II data.
  • Related Link: Morgan Stanley Sees Drug Pricing Still An Overhang For These Names

  • Ascendis Pharma A/S ASND: The company is ramping up manufacturing ahead of Ph. III trial in growth deficiency patients.
  • BioMarin Pharmaceutical Inc. BMRN: The company has a scheduled PDUFA date of December 27.
  • Cidara Therapeutics Inc CDTX: The company is executing well on CD101 development.
  • Dicerna Pharmaceuticals Inc DRNA: A decision on the fate of DCR-MYC is expected by the end of 2016.
  • Other Names

    In addition to the specific names mentioned above, Leerink also sees potential upcoming catalysts for the following Outperform-rated names in the space:

    • Auris Medical Holding AG EARS
    • Epizyme Inc EPZM
    • Fate Therapeutics Inc FATE
    • Amicus Therapeutics, Inc. FOLD
    • Insmed Incorporated INSM
    • ProQR Therapeutics NV PRQR
    • Uniqure NV> QURE
    • Raptor Pharmaceutical Corp. RPTP
    • Retrophin Inc RTRX
    • SAGE Therapeutics Inc SAGE
    • Acceleron Pharma Inc XLRN
    • Zafgen Inc ZFGN
    • Zogenix, Inc. ZGNX

    Disclosure: The author holds no position in the stocks mentioned.

    Image Credit: Public Domain
    Market News and Data brought to you by Benzinga APIs
    Comments
    Loading...
    date
    ▲▼
    ticker
    ▲▼
    name
    ▲▼
    Price Target
    ▲▼
    Upside/Downside
    ▲▼
    Recommendation
    ▲▼
    Firm
    ▲▼
    Posted In: Analyst ColorBiotechLong IdeasTop StoriesAnalyst RatingsTrading IdeasGeneralBiopharmaceuticalJoseph SchwartzLeerink
    Benzinga simplifies the market for smarter investing

    Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

    Join Now: Free!